References
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613
- Writing Group for Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
- Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric 2005; 8(Suppl 3)4–12
- Oelkers W HK. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005; 8(Suppl 3)19–27
- Lobo R A. The rationale for low-dose hormonal therapy. Endocrine 2004; 24: 217–221
- Oelkers W. Drospirenone, a progestogen with antimineralocortical properties: a short review. Mol Endocrin Cell Endocrinol 2004; 217: 255–261
- Rubig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6(Suppl 3)49–54
- Foidart J. -M. Added benefits of drospirenone for compliance. Climacteric 2005; 8(Suppl 3)28–34
- MacGregor G A, He F J. Importance of controlling blood pressure. Climacteric 2005; 8(Suppl 3)13–18
- Christiansen C. Effects of drospirenone/estrogen combinations on bone metabolism. Climacteric 2005; 8(Suppl 3)35–41